Pfizer Inc. $PFE Holdings Increased by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG increased its position in Pfizer Inc. (NYSE:PFE) by 5.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 338,410 shares of the biopharmaceutical company’s stock after buying an additional 18,032 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Pfizer were worth $9,651,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. Russell Investments Group Ltd. increased its position in Pfizer by 15.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock valued at $132,365,000 after buying an additional 745,213 shares in the last quarter. Handelsbanken Fonder AB raised its stake in Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock worth $59,295,000 after buying an additional 232,528 shares during the period. Leuthold Group LLC bought a new position in Pfizer in the second quarter worth approximately $4,887,000. Park National Corp OH lifted its holdings in shares of Pfizer by 332.1% in the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock worth $5,829,000 after purchasing an additional 186,053 shares in the last quarter. Finally, 111 Capital bought a new stake in Pfizer during the 2nd quarter valued at $3,706,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on PFE. HSBC upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, September 10th. Scotiabank lifted their price objective on shares of Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, October 13th. Five analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.72.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is being viewed as a potential value-and-income turnaround. Its forward P/E near 10, substantial dividend and recent price momentum are attracting investors rotating from technology and artificial-intelligence stocks into defensive healthcare companies. Pfizer’s Stock Is Finally Showing Signs of Life
• Positive Sentiment: The broader biotechnology and pharmaceutical sector has shown relative strength during recent market weakness. Pfizer’s stability, recurring drug demand and proximity to its annual high make it one of the large-cap healthcare names investors are watching for further upside. Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
• Positive Sentiment: Pfizer’s oncology strategy remains an important part of the turnaround narrative, with recent cancer approvals and a multibillion-dollar oncology alliance cited as evidence of pipeline and portfolio renewal. What Pfizer Bulls Got Right
• Neutral Sentiment: Analysts remain cautious: Wells Fargo and RBC Capital reiterated Hold ratings, indicating that Pfizer’s valuation and dividend are attractive but the turnaround still needs to demonstrate durable earnings growth. Pfizer Gets a Hold from Wells Fargo
• Negative Sentiment: Investors are questioning whether Pfizer’s dividend is adequately covered by cash flow. The dividend freeze and high payout burden could limit financial flexibility if revenue remains pressured. Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow
• Negative Sentiment: Upcoming results will be closely scrutinized for vaccine demand, pricing pressure and performance outside oncology, leaving execution and earnings visibility as key risks. Pfizer’s Non-Oncology Performance in Q3

Pfizer Stock Up 2.3%

Pfizer stock traded up $0.69 during trading on Tuesday, hitting $30.12. 16,798,089 shares of the company were exchanged, compared to its average volume of 39,972,082. The business’s 50 day moving average is $28.05 and its 200 day moving average is $26.57. Pfizer Inc. has a 52 week low of $23.62 and a 52 week high of $30.23. The company has a market capitalization of $171.70 billion, a P/E ratio of 39.64, a PEG ratio of 2.01 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the business earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 5.7%. Pfizer’s dividend payout ratio is currently 226.32%.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.